2 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
Follow PureTech: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| LYT-100 in Post-acute COVID-19 Respiratory Disease LYT-100, Placebo - Covid19, Post-acute COVID-19 Respiratory Disease | Phase 2 | Terminated | PureTech | 185 | 2020-12-11 | 2026-06-23 |
| LYT-100 in Patients With BCRL LYT-100 BCRL, Placebo BCRL - Breast Cancer Related Lymphoedema, Lymphoedema | Phase 2 | Terminated | PureTech | 50 | 2020-03-01 | 2024-04-23 |
COVID-19 (1) · Lung Diseases, Interstitial (1) · Lymphedema (1) · Post-Acute COVID-19 Syndrome (1) · Pulmonary Fibrosis (1)
pirfenidone (2)
United States (2) · Argentina (1) · Australia (1) · Brazil (1) · Moldova (1) · Philippines (1) · Romania (1) · Ukraine (1) · United Kingdom (1)
Toby Maher, MD (1)